SAN DIEGO, April 18, 2025 – Robbins LLP is reminding shareholders about the class action lawsuit filed on behalf of individuals and entities who acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities tied to the registration statement and prospectus for the company’s September 2024 initial public offering. Zenas BioPharma describes itself as a “clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need.”
For additional details, submit a form, contact attorney Aaron Dumas, Jr., or call (800) 350-6003.
The Allegations: Robbins LLP is currently investigating claims that Zenas BioPharma, Inc. (ZBIO) may have misled investors during its IPO.
The lawsuit alleges that Zenas BioPharma’s IPO documents failed to accurately state how long the company could fund operations with existing cash and IPO proceeds. On November 12, 2024, Zenas BioPharma’s Form 10-Q filing with the SEC for the quarter ending September 30, 2024, indicated the company could fund operations for twelve months, contradicting the Registration Statement’s claim of twenty-four months. Since the IPO, Zenas BioPharma’s stock price has significantly decreased due to the disclosure of these material omissions. On April 15, 2025, the closing price of Zenas BioPharma stock was $8.72, which is 48.7% lower than the IPO price.
What Now: You might be eligible to join the class action against Zenas BioPharma, Inc. Those seeking to be lead plaintiff must submit their filings to the court by June 16, 2025. The lead plaintiff represents the class members and guides the litigation. Participation is not required to be eligible for any potential recovery. You can remain an absent class member by taking no action. For more details, click .
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: Robbins LLP is a well-known leader in shareholder rights litigation. Since 2002, its attorneys and staff have focused on helping shareholders recover losses, improve corporate governance, and hold executives accountable.
To receive notification about a settlement in the Zenas BioPharma, Inc. class action or to receive alerts about corporate misconduct, sign up today.
Attorney Advertising. Past results do not guarantee a similar outcome.
SOURCE Robbins LLP
“`